These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35666466)

  • 21. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein.
    Otsubo R; Minamitani T; Kobiyama K; Fujita J; Ito T; Ueno S; Anzai I; Tanino H; Aoyama H; Matsuura Y; Namba K; Imadome KI; Ishii KJ; Tsumoto K; Kamitani W; Yasui T
    Sci Rep; 2022 Nov; 12(1):20120. PubMed ID: 36418391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.
    Wayham NP; Niedecken AR; Simons JF; Chiang YY; Medina-Cucurella AV; Mizrahi RA; Wagner EK; Gras A; Segal I; Witte P; Enstrom A; Bountouvas A; Nelson SM; Weinberger T; Tan D; Asensio MA; Subramanian A; Lim YW; Adler AS; Keating SM
    J Infect Dis; 2023 Aug; 228(5):555-563. PubMed ID: 37062677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.
    Ling Z; Yi C; Sun X; Yang Z; Sun B
    Sci China Life Sci; 2023 Apr; 66(4):658-678. PubMed ID: 36443513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery.
    Zhang X; Zhang H; Li T; Chen S; Luo F; Zhou J; Zheng P; Song S; Wu Y; Jin T; Tang N; Jin A; Yang C; Cheng G; Gong R; Chiu S; Huang A
    Signal Transduct Target Ther; 2022 Aug; 7(1):301. PubMed ID: 36042204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
    Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
    mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.
    Schulz SR; Hoffmann M; Roth E; Pracht K; Burnett DL; Mazigi O; Schuh W; Manger B; Mielenz D; Goodnow CC; Christ D; Pöhlmann S; Jäck HM
    Eur J Immunol; 2022 Jun; 52(6):970-977. PubMed ID: 35253229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
    Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
    One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
    Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
    Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transchromosomic bovines-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1, and influenza A virus.
    Saied AA; Nascimento MSL; do Nascimento Rangel AH; Skowron K; Grudlewska-Buda K; Dhama K; Shah J; Abdeen A; El-Mayet FS; Ahmed H; Metwally AA
    J Med Virol; 2022 Oct; 94(10):4599-4610. PubMed ID: 35655326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.
    Song R; Zeng G; Yu J; Meng X; Chen X; Li J; Xie X; Lian X; Zhang Z; Cao Y; Yin W; Jin R
    Emerg Microbes Infect; 2023 Dec; 12(1):2212806. PubMed ID: 37157134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies.
    Furuse Y
    J Med Virol; 2023 Jan; 95(1):e28275. PubMed ID: 36326059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
    Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Seo JM; Kang B; Song R; Noh H; Kim C; Kim JI; Kim M; Ryu DK; Lee MH; Yang JS; Kim KC; Lee JY; Lee H; Woo HM; Kim JW; Choi JA; Song M; Tomaszewska-Kiecana M; Wołowik A; Kulesza A; Kim S; Ahn K; Jung N; Lee SY
    Emerg Microbes Infect; 2022 Dec; 11(1):2315-2325. PubMed ID: 36006772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
    Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
    Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs.
    Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W
    Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.